{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-301414","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2026-07-13T10:30:23+00:00","discovered_at":"2026-07-13T10:35:10.426563+00:00","generated_at":"2026-07-13T10:35:19.930314+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Agenus raises $85M upfront (up to $340M) to fund registrational Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer","bullets":["Private placement of $85M upfront gross proceeds, plus up to $255M from warrant exercise; total up to $340M.","Proceeds to fund ROBBIN Phase 3 trial in neoadjuvant MSS colon cancer; expected runway through year-end 2031 if warrants exercised.","ROBBIN trial to enroll 850 patients, primary endpoint EFS; first patient dosed Q1 2027, interim pathologic response data H2 2027.","Discontinuing financial support for BATTMAN Phase 3 in late-line metastatic MSS CRC.","Phase 2 data: pathologic response ~60-70%, MPR ~35-40%, pCR ~30%; all patients disease-free at median 9-18 months follow-up."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-301414","json":"https://secwatch.observer/filing/0001193125-26-301414.json","markdown":"https://secwatch.observer/filing/0001193125-26-301414.md","text":"https://secwatch.observer/filing/0001193125-26-301414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/0001193125-26-301414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526301414/d111026d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T10:35:19.930314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}